MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Acquires $62,937.00 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero purchased 46,620 shares of the stock in a transaction dated Friday, August 28th. The stock was purchased at an average cost of $1.35 per share, for a total transaction of $62,937.00. Following the completion of the purchase, the director directly owned 735,701 shares of the company’s stock, valued at approximately $993,196.35. The trade was a 6.77% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Ramiro Guerrero also recently made the following trade(s):

• On Thursday, August 27th, Ramiro Guerrero acquired 78,239 shares of MAIA Biotechnology stock. The stock was purchased at an average cost of $1.39 per share, with a total value of $108,752.21.
• On Wednesday, August 26th, Ramiro Guerrero acquired 8,931 shares of MAIA Biotechnology stock. The stock was purchased at an average cost of $1.39 per share, with a total value of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero acquired 1,794 shares of MAIA Biotechnology stock. The stock was purchased at an average price of $1.33 per share, for a total transaction of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero bought 11,899 shares of MAIA Biotechnology stock. The shares were acquired at an average cost of $1.37 per share, for a total transaction of $16,301.63.

MAIA Biotechnology Stock Down 2.9%

MAIA Biotechnology stock opened at $1.33 on Friday. MAIA Biotechnology, Inc. has a 52-week low of $0.87 and a 52-week high of $3.19. The firm has a market capitalization of $80.90 million, a price-to-earnings ratio of -2.15 and a beta of 0.25. The company has a fifty day simple moving average of $1.37 and a 200-day simple moving average of $1.43.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, research analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Centric Wealth Management purchased a new stake in shares of MAIA Biotechnology in the second quarter valued at approximately $1,107,000. Solas Capital Management LLC purchased a new position in MAIA Biotechnology during the second quarter worth approximately $4,364,000. Cable Car Capital LP purchased a new position in MAIA Biotechnology during the second quarter worth approximately $741,000. Susquehanna International Group LLP acquired a new position in MAIA Biotechnology during the second quarter worth $51,000. Finally, BlackRock Inc. acquired a new position in MAIA Biotechnology during the second quarter worth $580,000. 5.65% of the stock is owned by hedge funds and other institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.